Serge Leyvraz

14.5k total citations · 2 hit papers
214 papers, 8.5k citations indexed

About

Serge Leyvraz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Serge Leyvraz has authored 214 papers receiving a total of 8.5k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Oncology, 79 papers in Pulmonary and Respiratory Medicine and 42 papers in Molecular Biology. Recurrent topics in Serge Leyvraz's work include Ocular Oncology and Treatments (30 papers), Immunotherapy and Immune Responses (28 papers) and Lung Cancer Treatments and Mutations (27 papers). Serge Leyvraz is often cited by papers focused on Ocular Oncology and Treatments (30 papers), Immunotherapy and Immune Responses (28 papers) and Lung Cancer Treatments and Mutations (27 papers). Serge Leyvraz collaborates with scholars based in Switzerland, Germany and France. Serge Leyvraz's co-authors include Roger Stupp, Laurent A. Décosterd, Thierry Buclin, Ferdy J. Lejeune, Chantal Csajka, Jean‐Yves Blay, Sandrine Ostermann, Jaap Verweij, Axel Le Cesne and Paolo G. Casali and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Serge Leyvraz

207 papers receiving 8.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

2006 654 citations Axel Le Cesne, Jean‐Yves Blay et al. European Journal of Cancer profile →
Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide

2002 630 citations Roger Stupp, Pierre-Yves Dietrich et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Serge Leyvraz

Since Specialization

Citations

This map shows the geographic impact of Serge Leyvraz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Serge Leyvraz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Serge Leyvraz more than expected).

Fields of papers citing papers by Serge Leyvraz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Serge Leyvraz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Serge Leyvraz. The network helps show where Serge Leyvraz may publish in the future.

Co-authorship network of co-authors of Serge Leyvraz

This figure shows the co-authorship network connecting the top 25 collaborators of Serge Leyvraz. A scholar is included among the top collaborators of Serge Leyvraz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Serge Leyvraz. Serge Leyvraz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Direct genetic transformation bypasses tumor-associated DNA methylation alterations 2025 ·Genome biology ·Sara Hetzel, Eran Hodis, (unknown), Alexander Kovacsovics, Kathleen E. Steinmann, Andreas Gnirke, Meiying Cui, Daniel McQuaid, (unknown), (unknown), Mandar D. Muzumdar, Serge Leyvraz, Ulrich Keilholz, Marie‐Laure Yaspo, Aviv Regev, Helene Kretzmer, Zachary D. Smith, Alexander Meissner	2
2	Long-term efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion thyroid carcinoma (TC). 2024 ·Journal of Clinical Oncology ·Maria E. Cabanillas, (unknown), Marcia S. Brose, Ray McDermott, (unknown), Jessica R. Bauman, Michela Casanova, Shivaani Kummar, Se‐Hoon Lee, Serge Leyvraz, Do‐Youn Oh, Lin Shen, (unknown), (unknown), Chiara Mussi, David S. Hong, Alexander Drilon, Steven G. Waguespack	4
3	A diagnostic challenge of KIT p.V559D and BRAF p.G469A mutations in a paragastric mass 2024 ·The Oncologist ·Stefan Habringer, Jana Ihlow, (unknown), (unknown), Max Schmidt, (unknown), Maren Knödler, Serge Leyvraz, (unknown), Bruno V. Sinn, Georg Maschmeyer, (unknown), Manuela Benary, Claus‐Eric Ott, Ingeborg Tinhofer, Reinhold Schäfer, Markus Möbs, Ulrich Keller, Ulrich Keilholz, Damian Rieke	0
4	Base-excision repair pathway shapes 5-methylcytosine deamination signatures in pan-cancer genomes 2024 ·Nature Communications ·André Bortolini Silveira, Alexandre Houy, Olivier Ganier, (unknown), (unknown), Anne Vincent‐Salomon, Nathalie Cassoux, Pascale Mariani, Gaëlle Pierron, Serge Leyvraz, Damian Rieke, Alberto Pïcca, Franck Bielle, Marie‐Laure Yaspo, Manuel Rodrigues, Marc‐Henri Stern	5
5	Tumor mutational burden as a predictive biomarker for molecularly matched therapy in two independent pan-cancer cohorts. 2023 ·Journal of Clinical Oncology ·Damian Rieke, (unknown), Manuela Benary, Peter Horak, Mario Lamping, Sebastian Stintzing, Inge Tinhofer, Serge Leyvraz, Reinhold Schäfer, Frederick Klauschen, Ulrich Keller, Albrecht Stenzinger, (unknown), Razelle Kurzrock, Ivan Jelas, Ulrich Keilholz	1
6	535P Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase (TRK) fusion cancer 2021 ·Annals of Oncology ·Marcia S. Brose, (unknown), Daniel Shao-Weng Tan, Shivaani Kummar, W. Marston Linehan, Ray McDermott, (unknown), Makoto Tahara, Ulrik Lassen, Serge Leyvraz, Jay Patel, (unknown), (unknown), Nicoletta Brega, David S. Hong, A. Drilon	1
7	Support of a molecular tumour board by an evidence-based decision management system for precision oncology 2020 ·European Journal of Cancer ·Mario Lamping, Manuela Benary, Serge Leyvraz, (unknown), Eric Blanc, T. Keßler, Moritz Schütte, Dido Lenze, Korinna Jöhrens, Susen Burock, Konrad Klinghammer, Sebastian Ochsenreither, Christine Sers, Reinhold Schäfer, Ingeborg Tinhofer, Dieter Beule, Frederick Klauschen, Marie‐Laure Yaspo, Ulrich Keilholz, Damian Rieke	16
8	1289P Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer 2020 ·Annals of Oncology ·Alexander Drilon, Víctor Moreno, Jyoti D. Patel, Ulrik Lassen, Benjamin Solomon, Lee S. Rosen, Serge Leyvraz, Daniel Shao-Weng Tan, (unknown), (unknown), Nicoletta Brega, Shivaani Kummar, Anna F. Farago	5
9	604TiP ON-TRK: A non-interventional study of larotrectinib in patients with TRK fusion cancer 2020 ·Annals of Oncology ·Serge Leyvraz, James Chih‐Hsin Yang, Paolo G. Casali, Gilberto de Castro, (unknown), Ulrik Lassen, Fernando López‐Ríos, Frédérique Penault‐Llorca, Alberto S. Pappo, Erin R. Rudzinski, Ghazaleh Tabatabai, Gilles Vassal, (unknown), Hendrik Nogai, Marc Fellous, Alexander Drilon, Marcia S. Brose, Jonathan C. Trent	2
10	1142P Treatment of metastatic uveal melanoma (mUM) through genomic profiling 2020 ·Annals of Oncology ·Serge Leyvraz, Mieke Schutte, Torsten Keßler, Thomas S. Risch, (unknown), Sebastian Ochsenreither, Damian Rieke, Vyacheslav Amstislavskiy, Christoph Wierling, Frederick Klauschen, (unknown), Mario Lamping, Ivan Jelas, Susen Burock, (unknown), Bodo Lange, Ch. Ulrich, Antonia M. Joussen, Ulrich Keilholz, (unknown)	0
11	A comparison of treatment recommendations by molecular tumor boards worldwide 2017 ·Annals of Oncology ·Damian Rieke, Serge Leyvraz, Susen Burock, Ulrich Keilholz	4
12	Long-Term Remission of an Aggressive Sebaceous Carcinoma following Chemotherapy 2014 ·Case Reports in Dermatology ·Angela Orcurto, (unknown), Wendy Jeanneret Sozzi, (unknown), Serge Leyvraz	23
13	Clinical pharmacokinetics of imatinib and its therapeutic relevance 2013 ·IRIS ·Nicolas Widmer, Verena Gotta, Amina Haouala, J.F. Blanc, Margaret von Mehren, Michel A. Duchosal, Serge Leyvraz, Chantal Csajka, Laurent A. Décosterd, Thierry Buclin	2
14	Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure 2012 ·Clinical Cancer Research ·George D. Demetri, (unknown), Patrick Schöffski, Manisha H. Shah, Jaap Verweij, Serge Leyvraz, Herbert I. Hurwitz, Antonio López–Pousa, Axel Le Cesne, David S. Goldstein, Luis Paz‐Ares, Jean‐Yves Blay, Grant A. McArthur, Qiang Xu, Xin Huang, Charles S. Harmon, Vanessa Tassell, Darrel P. Cohen, Paolo G. Casali	102
15	A Threefold Dose Intensity Treatment With Ifosfamide, Carboplatin, and Etoposide for Patients With Small Cell Lung Cancer: A Randomized Trial 2008 ·JNCI Journal of the National Cancer Institute ·Serge Leyvraz, S. Pampallona, Giovanni Martinelli, F. Ploner, Lucien Perey, Savina Aversa, Solange Peters, Paal Brunsvig, Ana Fernández Montés, Andrzej Lange, Ufuk Yılmaz, Giovanni Rosti, (unknown)	30
16	Sensitive Gene Expression Profiling of Human T Cell Subsets Reveals Parallel Post-Thymic Differentiation for CD4+ and CD8+ Lineages 2007 ·The Journal of Immunology ·Victor Appay, Andreas Bosio, (unknown), (unknown), Christian Biervert, (unknown), Estelle Devêvre, Daniel E. Speiser, Pedro Romero, Nathalie Rufer, Serge Leyvraz	35
17	L'annonce : d'une mauvaise nouvelle en oncologie : cancer 2005 ·Revue Médicale Suisse ·Verena Voelter, R.O. Mirimanoff, Friedrich Stiefel, (unknown), Serge Leyvraz	6
18	Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide breakdown → 2002 ·Journal of Clinical Oncology ·Roger Stupp, Pierre-Yves Dietrich, (unknown), Alessia Pica, Ivan Maillard, (unknown), Reto Meuli, Robert C. Janzer, Gianpaolo Pizzolato, Raymond Miralbell, François Porchet, Luca Regli, Nicolas de Tribolet, R.O. Mirimanoff, Serge Leyvraz	630
19	High-dose chemotherapy for solid tumors: results of the EBMT 2002 ·Critical Reviews in Oncology/Hematology ·Giovanni Rosti, Patrizia Ferrante, Jonathan A. Ledermann, Serge Leyvraz, Ruth Ladenstein, (unknown), John Crown, Claudio Dazzi, Anna Cariello, M. Marangolo	21
20	Is Cisplatin Required for the Treatment of Non-Small-Cell Lung Cancer? Experience and Preliminary Results of a Phase I/II Trial with Topotecan and Vinorelbine 2001 ·Oncology ·Roger Stupp, Alexandre Bodmer, B Duvoisin, Jean Bauer, Lucien Perey, (unknown), Nicolas Ketterer, Serge Leyvraz	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact